Our award-winning reporting has moved

Context provides news and analysis on three of the world’s most critical issues:

climate change, the impact of technology on society, and inclusive economies.

Rich, developing nations wrangle over COVID vaccine patents

by Reuters
Wednesday, 10 March 2021 21:07 GMT

A health worker shows a bottle of vaccine against the coronavirus disease (COVID-19) in Cairo, Egypt March 4, 2021. REUTERS/Mohamed Abd El Ghany

Image Caption and Rights Information

Wealthy countries are blocking proposals to boost fair distribution of jabs to poorer countries by waiving COVID vaccine patents

* Eighth discussion on TRIPS waiver ends in stalemate

* Two further meetings planned for April

* WTO head pushes idea of manufacturing alliance (Updates after meeting)

GENEVA, March 10 (Reuters) - Richer members of the World Trade Organization (WTO) blocked a push by over 80 developing countries on Wednesday to waive patent rights in an effort to boost production of COVID-19 vaccines for poor nations.

South Africa and India renewed their bid to waive rules of the WTO's Trade-Related Aspects of Intellectual Property (TRIPS) agreement, a move that could allow generic or other manufacturers to make more vaccines.

South Africa argued the current TRIPS system does not work, pointing to the failure to secure life-saving medicines during the HIV/AIDS pandemic that had cost at least 11 million African lives.

Medecins Sans Frontieres in October put together a letter signed by over 375 civil society organisations supporting the waiver.

The South Africa and India proposal was backed by dozens of largely developing countries at the WTO, but opposed by Western countries, including Britain, Switzerland, EU nations and the United States, which have large domestic pharmaceutical industries.

India is a major manufacturer of generics, although many of the largest generic companies are based in Western and developed countries, including Viatris, Sandoz and Teva.

Western nations argue protecting intellectual property rights encouraged research and innovation and that suspending those rights would not result in a sudden surge of vaccine supply.

In its eighth discussion on the topic since it was first raised in October, the WTO's TRIPS Council spent three hours debating, but failed to agree. Proposals need backing by a consensus of the WTO's 164 members to pass.

They did at least agree to discuss the matter twice again in April before the next scheduled TRIPS Council meeting on June 8-9.

Ngozi Okonjo-Iweala, who became WTO director-general on March 1, called the intensifying TRIPS discussions "vitally important," but said governments and businesses needed to act now to increase production, especially in emerging markets.

She said in a speech on Tuesday that manufacturers should come together with bodies such as the World Health Organization and vaccines alliance GAVI, whose board she used to chair, and business associations to look into options.

"We must make sure that in the end we deliver so that the millions of people who are waiting for us with bated breath know that we are working on concrete solutions," the former Nigerian finance and foreign minister said.

(Reporting by Philip Blenkinsop, Editing by William Maclean and Aurora Ellis)

Our Standards: The Thomson Reuters Trust Principles.